Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOVENTIX PLC Director's Dealing 2022

Oct 27, 2022

7520_dirs_2022-10-27_10add51d-b8f8-4095-9f73-8df587c0af1b.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

Bioventix Plc - Director Dealing

PR Newswire

London, October 26

Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has been notified that Bruce Hiscock, Chief Financial Officer of the Company, completed the following dealings in the Company’s ordinary shares of 5 pence in the Company ("Ordinary Shares"):

  • the transfer, via sale and purchase, of 204 Ordinary Shares into his ISA. Mr Hiscock sold 204 Ordinary Shares at a price of £33.41 from an account in his own name and bought 204 Ordinary Shares at a price of £34.00 to be held in his ISA; and
  • the additional purchase of 276 Ordinary Shares at a price of £34.00 into his ISA.

Following these transactions, Mr Hiscock’s total beneficial interest in the Company is now 700 Ordinary Shares, representing approximately 0.01 per cent. of the Company’s total issued share capital.

For further information please contact:

Bioventix plc

Peter Harrison
Chief Executive Officer Tel: 01252 728 001
finnCap Ltd

Geoff Nash/Simon Hicks/Abigail Kelly

Alice Lane
Corporate Finance

ECM
Tel: 020 7220 0500

1.Details of the person discharging managerial responsibilities / person closely associateda)NameBruce Hiscock2.Reason for the Notificationa)Position/statusChief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBioventix plcb)LEI213800225MHX7LZQY1084.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the Financial instrument, type of instrumentOrdinary SharesIdentification codeGB00B4QVDF07b)Nature of the transactionSale of Ordinary Sharesc)Price(s) and volume(s)

Volume(s) Prices (pence)
204 3,341

d)Aggregated information:

·Aggregated volume

·PriceSale of 204 Ordinary Shares at a price of 3,341p per Ordinary Sharee)Date of the transaction26 October 2022f)Place of the transactionLondon Stock Exchange, AIM Market (XLON)

1.Details of the person discharging managerial responsibilities / person closely associateda)NameBruce Hiscock2.Reason for the Notificationa)Position/statusChief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBioventix plcb)LEI213800225MHX7LZQY1084.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the Financial instrument, type of instrumentOrdinary SharesIdentification codeGB00B4QVDF07b)Nature of the transactionPurchase of Ordinary Sharesc)Price(s) and volume(s)

Volume(s) Prices (pence)
480 3,400

d)Aggregated information:

·Aggregated volume

·PricePurchase of 480 Ordinary Shares at a price of 3,400p per Ordinary Sharee)Date of the transaction26 October 2022f)Place of the transactionLondon Stock Exchange, AIM Market (XLON)